SCHEMBL5658015

SCHEMBL5658015

O=C(c1ccc2c(c1)OCCO2)c1ccc2[nH]c(=O)nc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CASP1 P29466 1/20 0.50
HSD17B10 Q99714 1/20 0.50
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
MAOB P27338 1/20 0.44
CHEK2 O96017 1/20 0.43
MAPT P10636 5/20 0.41
TGFBR1 P36897 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
CSNK1G2 P78368 1/20 0.40
PRKD1 Q15139 1/20 0.40
MAPK14 Q16539 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40
TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898281 0.85 KDM4E (0.62) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL3559250 0.83 KDM4E (0.55) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL5654518 0.83 KDM4E (0.55) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL3552671 0.83 KDM4E (0.55) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL5658645 0.81 NPC1 (0.47) NPSR1KDM4EMEN1KMT2AHSD17B10
SCHEMBL3556688 0.80 MEN1 (0.52) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL5550324 0.79 KDM4E (0.51) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL5023770 0.78 KDM4E (0.52) NPSR1KDM4EMEN1KMT2ACASP1
SCHEMBL5656566 0.75 FNTA (0.61)
SCHEMBL5656276 0.73 IP6K1 (0.51) NPSR1KDM4EMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 NPSR1 3609/4885KDM4E 1592/4885MEN1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.